These new suspects-neutrophils, B1a cells and pDCs-are not to be underestimated. They have been implicated, individually or synergistically, in other autoimmune and inflammatory disorders such as lupus and psoriasis. Therefore, drugs that interfere with these cells and pathways may also have applications in T1D. Nevertheless, the extremely narrow therapeutic opportunity afforded by these early and transient events complicates the possibility of intervention. The authors showed that, in principle, Z-VAD can effectively block apoptosis in very young NOD mice. In humans, most physiological beta cell apoptosis seems to occur between 5 months before birth and 3 months after birth 8 , and it is unknown whether this cell death event represents a precipitating event as in mice. If beta cell apoptosis does trigger such an immune response in humans, the extensive genetic variation between genetically susceptible people might dictate the nature of the immune cell types involved, the amplitude of the response and how long the immune event takes to resolve (independently of the physiological event). T1D prevention strategies rely on a number of biomarkers that, although they precede the onset of hyperglycemia and complete loss of beta cells, reflect subsequent events that are mainly associated with the adaptive immune response 10 . Although beta cell apoptotic events are uncommon past 3 months of age in babies 8 , islet autoantibodies, which are used as predictors of disease, are rarely detected before 6 months 9 . Thus, major advances in diagnostic tools and surrogate biomarkers are required to fill this gap by detecting the early immune events that affect human islets 10 .
MDSCs is more complex than simple induction of MDSC cell death. Gemcitabine and 5-fluorouracil seem to activate the proapoptotic protein Bax (Bcl2-associated X protein) in MDSCs, which leads to lysosome destabilization and the subsequent release of cathepsin B, an enzymatic lysosomal protease (Fig. 1) . Cathepsin B activates the NLRP3 (NACHT, LRR and PYD domains-containing protein 3, also known as cryopyrin) inflammasome, resulting in the production and release of immunomodulatory cytokines through caspase-1 activation. This process, which is dissociated from chemotherapy-induced MDSC cell death and occurs before it, reduces anticancer immunity and promotes tumor growth.
Caspase-1, formerly called interleukin-1β (IL-1β)-converting enzyme, is involved in mediating programmed cell death by promoting the cleavage of crucial intracellular proteins upon apoptopic activation; however, it seems to be also uniquely involved in the inflammatory response by cleaving the precursors of IL-1β, IL-18 and IL-33. The discovery of caspase-1 and its importance in IL-1β secretion was recognized 20 years ago when it was shown that caspase-1 inhibitors reduced secretion of Conventional chemotherapy as a major treatment modality for advanced cancer, although not often curative, can achieve high response rates. Recent evidence suggests that this therapeutic efficacy relies in part on the capacity of chemotherapeutic agents to interact with the immune system 1 . Chemotherapy is thought to induce various tumor cell death modalities, which can lead to the release of tumor-derived antigens that can be engulfed and processed by immune cells, resulting in their activation and induction of antitumor immunity. For instance, treatment with Taxol (paclitaxel), an antimicrotubule agent, in advanced ovarian cancer was shown to upregulate the cytotoxic T cell function that has been attributed to Taxol-induced tumor apoptosis and the accessibility of tumor antigens 2 .
Chemotherapeutic agents may also interfere with the molecular and cellular mechanisms responsible for tumor-induced immune tolerance. Human colon carcinoma cells treated with 5-fluorouracil, an antimetabolite agent, became more sensitive to lysis by tumor-specific cytotoxic T cells 3 . Cytotoxic drugs such as cisplatin, doxorubicin, mitomycin C and camptothecin also primed tumor cells to elimination by immune cells, including natural killer or cytotoxic T lympho cytes 4 . Many chemo therapeutic agents can directly stimulate functional activity of antigen-presenting cells such as dendritic cells 1 .
Beneficial immunomodulatory effects of chemotherapy might also be associated with lymphodepletion, that is, elimination of immunosuppressive regulatory T cells and poorly functional antitumor T lymphocytes. For example, a DNA-alkylating agent such as cyclophosphamide might act via the depletion of regulatory T cells 5 . Gemcitabine, an antimetabolite agent, attenuates the immunosuppressive properties of the tumor microenvironment by eliminating myeloid-derived suppressor cells (MDSCs) 6 , which are considered a key immunosuppressive regulatory cell subset in many types of cancer.
In this issue of Nature Medicine, Bruchard et al. 7 show that the effect of gemcitabine on active IL-1β from monocytes 8 . Since that time, studies on caspase-1-deficient mice have confirmed its role in controlling inflammation. Bruchard et al. 7 found that MDSCs from tumor-bearing mice treated with gemcitabine or 5-fluorouracil secreted IL-1β in a caspase-1-dependent manner (Fig. 1) . In vivo, IL-1β was found in the serum of tumor-bearing mice after 5-fluorouracil administration. MDSC depletion before 5-fluorouracil treatment prevented IL-1β elevation, suggesting that its production was mainly due to MDSCs.
Although IL-1β is known to be involved in the regulation of inflammation, immunity and hemopoiesis, its role in carcinogenesis is also established. IL-1β recruits different myeloid regulatory cells, including MDSCs, that promote tumor-mediated immunosuppression, supports malignant cell invasiveness and metastasis and may also confer a proliferative advantage to cancerous cells through autocrine mechanisms. The authors showed that chemotherapy-induced IL-1β expression by MDSCs markedly decreased the antitumor effect of chemotherapy in lymphoma, melanoma, mammary cancer and lung cancer animal models 7 . Administration of the soluble IL-1 receptor antagonist anakinra enhanced the antitumor efficacy of 5-fluorouracil, leading to tumor regression in about 50% of treated animals.
How does IL-1β affect the antitumor immunity? The protumorigenic effect of MDSCderived IL-1β seemed to be mediated by T cell polarization toward a T helper type 17 (T H 17) phenotype, as CD4 + T cell depletion enhanced the antitumor effect of 5-fluorouracil in an IL-1-dependent manner 7 . Ex vivo studies confirmed that gemcitabine-and 5-fluorouracilinduced MDSC-mediated T cell differentiation into IL-17-producing CD4 + T cells was dependent on cathepsin B, Nlrp3, caspase-1 and IL-1. Notably, the antitumor effect of 5-fluorouracil was significantly stronger in IL-17-deficient mice, confirming that IL-1β-dependent T H 17 cell polarization of CD4 T cells limits the therapeutic efficacy of 5-fluorouracil.
Interestingly, optimal anticancer responses during chemotherapy with the anthracycline doxorubicin have been shown to require the IL-17-producing γδ T cell population, whose activation depended on IL-1β produced by dendritic cells in response to dying tumor cells 9 . Conventional helper CD4 + αβ T cells failed to produce IL-17 after doxorubicin chemotherapy. Thus, it seems that different chemotherapeutic agents may use similar molecular pathways affecting the immune responses, but, by targeting different cell subsets, these agents may cause even opposite effects on the antitumor immunity. As Bruchard et al. 7 
T H 17 cells are a unique subset of T cells that have important roles in the pathogenesis of inflammatory and autoimmune diseases. Although many studies have demonstrated potent antitumor functions for IL-17 and T H 17 cells 10 , T H 17 cells have also been shown to play an active part in tumor pathogenesis 11 . For instance, IL-17R deficiency increased CD8 + T cell numbers and reduced MDSC tumor infiltration, whereas systemic administration of IL-17 in lymphoma-or melanoma-bearing mice promoted tumor growth, enhanced the number of MDSCs and reduced CD8 + T cell tumor infiltration 12 . It is established that IL-17 is a proangiogenic factor that acts on endo thelial, stromal and cancerous cells and elicits vessel formation to induce tumor vascularization and promote tumor growth 13 . Therefore, IL-17 is a pleiotropic cytokine with both pro-and antitumorigenic effects, depending on the tumor environment context, degree of inflammation and stability of heterogeneous IL-17-producing cells. More studies are required to understand how chemo therapy affects different sources of IL-17 and how these effects alter the development of pro-and antitumor responses.
The results of Bruchard et al. 7 studies have revealed that gemcitabine and 5-fluorouracil, in addition to depleting immunosuppressive MDSCs, also induce the release of cathepsin B from lysosomes and the activation of the NLRP3 inflammasome and caspase-1, which causes IL-1β secretion from MDSCs, resulting in IL-17 production by T cells and promotion of tumor growth. The most important strength of the Bruchard et al. 7 study is in providing, probably for the first time, a mechanism-based, Cathepsin B directly interacts with the leucine-rich-repeat (LRR) domain of NLRP3 inflammasome (which comprises the NLR protein Nlrp3, the adaptor ASC and pro-caspase-1) causing its activation. After its assembly, the inflammasome converts pro-caspase-1 into an active enzyme, which then cleaves pro-IL-1β, a precursor of IL-1β, resulting in the formation of a biologically active cytokine that is released from MDSCs. IL-1β is an important regulator of CD4 + T helper cell polarization and drives the emergence of T H 17 subsets, which produce IL-17. Soluble IL-1β may also stimulate MDSC expansion and attraction. Pleiotropic cytokine IL-17 plays an active part in tumor pathogenesis and progression by enhancing the emergence of immunosuppressor MDSCs to the tumor site, reducing tumor infiltration by cytotoxic T cells and inducing intratumor neoangiogenesis. ASC, apoptosis-associated speck-like protein containing a CARD domain. rather than empirical, rationale for combination of specific chemotherapeutic agents with specific immunotherapeutic approaches for cancer treatment-IL-1 receptor antagonist was shown to enhance the antitumor effect of 5-fluorouracil. This finding has clear clinical implications because it suggests that only certain chemotherapeutic and immunomodulatory agents should be combined for increasing the efficacy of anticancer therapy.
Understanding the immunological events occurring in both animal models and patients undergoing chemotherapy should guide decisions about the development of appropriate combinations and scheduling for the integration of chemotherapy with immunotherapy. The study by Bruchard et al. 7 represents an excellent example of how comprehensive exploration of the interplay between chemotherapeutic drugs, tumor cell death and immune cells can improve diagnostic, prognostic and therapeutic management of cancer.
pathways from either β2AR or GPR3 might be involved in the regulation of Aβ production.
As their name indicates, GPCRs directly interact with G proteins to mediate a variety of intracellular signaling events, such as the generation of cyclic AMP from adenylate cyclase. However, GPCRs can also directly interact with another family of adaptor proteins, the arrestins, resulting in receptor internalization and desensitization as well as signaling that is distinct from and independent of G proteins 8 . Thathiah et al. 4 first found that mRNA levels of one of these proteins, β-arrestin 2, were generally elevated in post-mortem human Alzheimer's brains, whereas mRNA of the related β-arrestin 1 was decreased. Subsequent cellular experiments revealed that overexpression of β-arrestin 2 increased Aβ secretion. In contrast, knockdown of β-arrestin 2 decreased Aβ secretion, an effect that was not seen when β-arrestin 1 was knocked down. Embryonic neuronal cultures from mice deficient in either β-arrestin 1 (Arrb1 −/− ) or β-arrestin 2 (Arrb2 −/− ) gave similar results, suggesting that the latter is involved in mediating the effect of GPCRs in Aβ production. Another recent study, however, showed reduced Aβ levels in Arrb1 −/− mouse brains, an inconsistency that will require further experiments to resolve 9 .
Arrb2 +/+ and Arrb2 −/− neuronal cultures were then used to explore how GPR3 might affect Aβ production 4 . Overexpression of GPR3 elevated Aβ secretion from the Arrb2 +/+ neuronal cultures, as seen before 6 , but did not Amyloid-β peptide (Aβ) is the principal protein component of the characteristic cerebral plaques of Alzheimer's disease, and a compelling body of evidence compiled over more than 25 years points to Aβ as a key pathogenic entity 1 . However, despite enormous investments in time, energy and money, a safe and efficacious Aβ-targeting strategy has yet to successfully emerge from clinical trials 2 . A better understanding of how Aβ production is regulated might reveal new insights into the pathogenesis of Alzheimer's disease and suggest new targets that are more 'druggable' than those currently being pursued.
The discovery that certain G proteincoupled receptors (GPCRs), including the β2-adrenergic receptor (β2AR) and an orphan receptor called GPR3, can regulate Aβ production 3 has offered fresh hope for Alzheimer's drug discovery, as roughly half of current prescription drugs target GPCRs, and many of these are indicated for disorders of the central nervous system. However, our understanding of how β2AR and GPR3 alter Aβ production has been limited, particularly with regard to which signaling events from these receptors might be involved. In this issue of Nature Medicine, Thathiah et al. 4 now provide provocative evidence that the adaptor protein β-arrestin 2 mediates the Aβ-altering effects of these GPCRs by promoting Aβ generation. This newly uncovered function of β-arrestin 2 suggests it could be targeted to decrease amyloid pathology in patients with Alzheimer's disease.
Previous studies 5, 6 showed that β2AR and GPR3 exert their effects on Aβ production at the level of γ-secretase, which, along with β-secretase, cuts out Aβ from its protein precursor, APP (Fig. 1) . γ-secretase is a membrane-embedded complex of four proteins, presenilin, nicastrin, Aph-1 (anterior pharynxdefective 1) and Pen-2 (presenilin enhancer 2), with presenilin being the catalytic component containing an aspartyl protease active site 7 . Agonist-induced endocytosis of β2AR in cell culture resulted in co-internalization of the γ-secretase complex, bringing the enzyme to late endosomes, where a more acidic environment may be more favorable for γ-secretase activity 5 . Conversely, a β2AR antagonist inhibited Aβ production and reduced cerebral plaques in a transgenic Alzheimer's mouse model 5 . Such pharmacological experiments were not possible for GPR3, which has no known ligands. However, GPR3 shows constitutive activity in cell culture; overexpression of GPR3 increased Aβ production, whereas its genetic ablation, in both cultured cells and an Alzheimer's mouse model, reduced Aβ levels 6 
